3D-QSAR Using the GRID/GOLPE Approach

Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction

Volumn 27, Issue , 2006, Pages 145-170

  Sippl, Wolfgang ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

3D QSAR using the GRID GOLPE approach; Acetylcholinesterase inhibitors; Estrogen receptor ligands; GRID GOLPE application examples; Molecular interaction fields

Indexed keywords

3D-QSAR; ACETYLCHOLINESTERASE INHIBITORS; APPLICATION EXAMPLES; ESTROGEN RECEPTOR; MOLECULAR INTERACTION FIELDS;

EID: 85018917153     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527607676.ch7     Document Type: Chapter

References (78)

1. Hansch, C., Leo, A. Exploring QSAR. Fundamentals and Applications in Chemistry and Biology, American Chemical Society, Washington DC, 1995.
2. Kubinyi, H. QSAR and 3D-QSAR in Drug Design, Drug Discovery Today 1997, 2, 457-467.
3. Cramer III, R. D., Patterson, D. E., Bunce, J. D. Comparative Molecular Field Analysis (CoMFA) 1. Effect of Shape on Binding of Steroids to Carrier Proteins, J. Am. Chem. Soc. 1988, 110, 5959-5967.
4. GRID/GOLPE, www.moldiscovery.com, Molecular Discovery, UK.
5. Kuntz, J.D. Structure-based Strategies for Drug Design and Discovery, Science, 1992, 257, 1078-1082.
6. Kim, K. Non-linear Dependencies in CoMFA. J. Comput.-Aided Mol. Des. 1993, 7, 71-82.
7. Folkers, G., Merz, A., Rognan, D. CoMFA: Scope and Limitations, in 3D-QSAR in Drug Design. Theory, Methods and Applications, Kubinyi, H., (ed.), ESCOM Science Publishers B.V., Leiden, 1993.
8. Klebe, G., Abraham, U. On the Prediction of Binding Properties of Drug Molecules by Comparative Molecular Field Analysis, J. Med. Chem. 1993, 36, 70-80.
9. Sippl, W. Development of Biologically Active Molecules by Combining 3D-QSAR and Structure-based Design Methods, J. Comput.-Aided Mol. Des. 2002, 16, 825-830.
10. Höltje, H.-D., Sippl. W., Rognan, D., Folkers, G., Molecular Modeling - Basic Principles and Applications, Wiley-VCH, Weinheim, 2003.
11. Pastor, M., Cruciani, G., Watson, K. A Strategy for the Incorporation of Water Molecules Present in a Ligand Binding Site into a Three-Dimensional Quantitative Structure-Activity Relationship Analysis, J. Med. Chem. 1997, 40, 4089-4102.
12. Sippl, W., Contreras, J. M., Parrot, I., Rival, Y., Wermuth, C.G. Structure based 3D-QSAR and Design of Novel Acetylcholinesterase Inhibitors, J. Comput.-AidedMol. Des. 2001, 15, 395-10.
13. Classen-Houben, D., Sippl, W., Höltje, H.-D. Molecular Modeling on Ligand/ Receptor Complexes of Protein-Tyrosine-Phosphatase 1B, in EuroQSAR2002 Designing Drugs and Crop Protectants: Processes, Problems and Solutions, Ford, M., Livingstone, D., Dearden, J., Van de Waterbeemd, H., (eds.) Blackwell Publishing, Bournemouth, 2002.
14. Cinone, N., Höltje, H.-D., Carotti, A. Development of a Unique 3D Interaction Model of Endogenous and Synthetic Peripheral Benzodiazepine Receptor Ligands, J. Comput.-Aided Mol. Des. 2000, 14, 753-768.
15. Hammer, S., Spika, L., Sippl, W., Jessen, G., Kleuser, B., Höltje, H.-D., Schäfer-Korting, M. Glucocorticoid Receptor Interactions with Glucocorticoids: Evaluation by Molecular Modeling and Functional Analysis of Glucocorticoid Receptor Mutants, Steroids 2003, 68, 329-339.
16. Audouze, K., Ostergaard Nielsen, E., Peters D. New Series of Morpholine and 1, 4-Oxazepane Derivatives as Dopamine D4 Receptor Ligands: Synthesis and 3D-QSAR Model, J. Med. Chem. 2004, 47, 3089-3104.
17. Terp, G. E., Cruciani, G., Christensen, I. T., Jorgensen, F. S. Structural Differences of Matrix Metalloproteinases with Potential Implications for Inhibitor Selectivity Examined by the GRID/ CPCA Approach, J. Med. Chem. 2002, 45, 2676-2684.
18. Tervo, A. J., Nyronen, T. H., Ronkko, T., Poso, A. A Structure-Activity Relationship Study of Catechol-O-Methyltrans ferase Inhibitors Combining Molecular Docking and 3D-QSAR Methods, J. Comput.-Aided Mol. Des. 2003, 17, 797-810.
19. Kramer, B., Rarey, M., Lengauer, T. CASP2 Experiences with Docking Flexible Ligands Using FlexX, Proteins, 1997, Suppl. 1, 221-225.
20. Morris, G. M., Goodsell, D. S., Huey, R., Olson, A. J. Distributed Automatic Docking of Flexible Ligands to Proteins, J. Comput.-Aided Mol. Des. 1994, 8, 243-256.
21. Verdonk, M. L., Cole, J. C., Hartshorn, M., Murray, C., Taylor, R. D. Improved Protein-Ligand Docking using GOLD, Proteins 2003, 52, 609-623.
22. Meng, E., Shoichet, B. K., Kuntz. I. D. Automated Docking with Grid-based Energy Evaluation, J. Comput. Chem. 1992, 13, 505-524.
23. Kontoyianni, M., McClellan, L. M., Sokol, G. S. Evaluation of Docking Performance: Comparative Data on Docking Algorithms, J. Med. Chem. 2004, 47, 558-565.
24. Tame, J. R. H. Scoring Functions: A View from the Bench, J. Comput.-Aided Mol. Des. 1999, 13, 99-108.
25. Bohm, H. J. Prediction of Binding Constants of Protein Ligands: A Fast Method for the Prioritisation of Hits Obtained from De-novo Design or 3D Database Search Programs, J. Comput. Aided Mol. Des. 1998, 12, 309-323.
26. Wang, R., Lu, Y., Fang, X., Wang, S. An Extensive Test of 14 Scoring Functions Using the PDBbind Refined Set of 800 Protein-Ligand Complexes, J. Chem. Inf. Comput. Sci. 2004, 44, 2114-2125.
27. Perola, E., Walters, W. P., Charifson, P.S. A Detailed Comparison of Current Docking and Scoring Methods on Systems of Pharmaceutical Relevance, Proteins 2004, 56, 235-249.
28. Gohlke, H., Klebe, G. Approaches to the Description and Prediction of the Binding Affinity of Small Molecule Ligands to Macromolecular Receptors, Angew. Chem., Int. Ed. 2002, 41, 2644-2676.
29. Masukawa, K. M., Kollman, P. A., Kuntz, I. D. Investigation of Neuraminidase-Substrate Recognition Using Molecular Dynamics and Free Energy Calculations, J. Med. Chem. 2003, 46, 5628-5637.
30. Huang, D., Caflisch, A. Efficient Evaluation of Binding Free Energy Using Continuum Electrostatics Solvation, J. Med. Chem. 2004, 47, 5791-5797
31. Waller, C. L., Oprea, T. I., Giolitti, A., Marshall, G.R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules, J. Med. Chem. 1993, 36, 4152-4160.
32. De Priest, S. A., et al. 3D-QSAR of Angiotensin-Converting Enzyme and Thermolysin Inhibitors: A Comparison of CoMFA Models Based on Deduced and Experimentally Determined Active Site Geometries, J. Am. Chem. Soc. 1993, 115, 5372-5384.
33. Cho, S. J, Garsia, M. L., Bier, J., Tropsha, A. Structure-based Alignment and Comparative Molecular Field Analysis of Acetylcholinesterase Inhibitors, J. Med. Chem. 1996, 39, 5064-5071.
34. Vaz, R. J., McLean, L. R., Pelton, J. T Evaluation of Proposed Modes of Binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxyl]phenyl]-3-(7-amidino-2-naphtyl)-propanoic Acid Hydrochloride and some Analogs to Factor Xa Using a Comparative Molecular Field Analysis, J. Comput.-Aided Mol. Des. 1998, 12, 99-110.
35. Sippl, W. Receptor-based 3D Quantitative Structure-Activity Relationships of Estrogen Receptor Ligands. J. Comput. Aided. Mol. Des., 2000, 14, 559-572.
36. Sippl, W. Binding Affinity Prediction of Novel Estrogen Receptor Ligands Using Receptor-based 3D-QSAR Methods, Bioorg. Med. Chem. 2002, 10, 3741-3755.
37. Ortiz, A. R., Pisabarro, M. T., Gago, F., Wade, R. C. Prediction of Drug Binding Affinities by Comparative Binding Energy Analysis, J. Med. Chem. 1995, 38, 2681-2691.
38. Holloway, M. K. et al. A Priori Prediction of Activity for HIV-1 Protease Inhibitors Employing Energy Minimization in the Active Site, J. Med. Chem. 1995, 38, 305-317.
39. Lozano, J. J., Pastor, M., Cruciani, G., Gaedt, K., Centeno, N. B., Gago, F., Sanz, F. 3D-QSAR Methods on the Basis of Ligand-Receptor Complexes. Application of Combine and GRID/ GOLPE Methodologies to a Series of CYP1A2 Inhibitors, J. Comput.-Aided Mol. Des. 2000, 13, 341-353.
40. Cramer III, R. D., Patterson, D. E., Bunce, J. D. Comparative Molecular Field Analysis CoMFA): 1. Effect of Shape on Binding of Steroids to Carrier Proteins, J. Am. Chem. Soc. 1988, 110, 5959-5967.
41. Goodford, P. J. A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules, J. Med. Chem. 1985, 28, 849-857.
42. Cruciani, G., Crivori, P., Carrupt, P.-A., Testa B. Molecular Fields in Quantitative Structure-Permeation Relationships, J. Mol. Struct. 2000, 503, 17-30.
43. Baroni, M., Constantino, G., Cruciani, G., Riganelli, D, Valigli, R., Clementi, S. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D-QSAR Problems, Quant. Struct.-Act. Relat. 1993, 12, 9-20.
44. Pastor, M., Cruciani, G., Clementi, S. Smart Region Definition: A New Way to Improve the Predictive Ability and Inter pretability of Three-Dimensional Quantitative Structure-Activity Relationships, J. Med. Chem. 1997, 40, 1455-1464.
45. Cruciani, G., Watson, K. Comparative Molecular Field Analysis Using GRID Force Field and GOLPE Variable Selection Methods in a Study of Inhibitors of Glycogen Phosphorylase b, J. Med. Chem. 1994, 37, 2589-2601.
46. Oprea, T. I., Garcia, A. E. Three-Dimensional Quantitative Structure-Activity Relationships of Steroid Aromatase Inhibitors, J. Comput.-Aided Mol. Des. 1996, 10, 186-200.
47. Golbraikh, A., Trophsa, A. Beware of q2! J. Mol. Graph. Model. 2002, 20, 269-276.
48. Kubinyi, H., Hamprecht, F. A., Mietzner, T. Three-Dimensional Quantitative Similarity-Activity Relationships (3D QSiAR) from SEAL Similarity Matrices, J. Med. Chem. 1998, 41, 2553-2564.
49. Golbraikh, A., Shen, M., Xiao, Z., Xiao, Y., Lee, K.-H., Tropsha, A. Rational selection of training and test sets for the development of validated QSAR models, J. Comput.-Aided Mol. Des. 2003, 17, 241-253.
50. Norinder, U. Single and Domain Made Variable Selection in 3D QSAR Applications, J. Chemomet. 1996, 10, 95-105.
51. Evans, R. M. The Steroid and Thyroid Hormone Receptor Superfamily, Science, 1988, 240, 889-895.
52. Von Angerer, E. The Estrogen Receptor as a Target for Rational Drug Design, Landes, Austin, USA, 1995.
53. Zeelen, F. J. Medicinal Chemistry of Steroids, Elsevier, Amsterdam, 1990.
54. Anstead, G. M., Carlson, K. E., Katzenellenbogen, J. A. The Estradiol Pharmacophore: Ligand Structure-Estrogen Receptor Binding Affinity Relationships and a Model for the Receptor Binding Site, Steroids, 1996, 62, 268-303.
55. Höltje, H.-D., Dall, N. A Molecular Modeling Study on the Hormone Binding Site of the Estrogen Receptor, Pharmazie 1993, 48, 243-246.
56. Lewis, D. F. V., Parker, M. G. and King, R. J. B. Molecular Modeling of the Human Estrogen Receptor and Ligand Interaction Based on Site-Directed Mutagenesis and Amino Acid Sequence Homology, J. Steroid. Biochem. Mol. Biol. 1995, 52, 55-65.
57. Goldstein, R. A., Katzenellenbogen, J. A., Luthey-Schulten, Z. A., Seielstad, D. A., Wolynes, P. G. Three-Dimensional Model for the Hormone Binding Domains of Steroid Receptors, Proc. Natl. Acad. Sci. USA 1993, 90, 9949-9953.
58. Lemesle-Varloot, L., Ojasoo, T., Mornon, J. P., Raynaud, J. P. A Model for the Determination of the 3D-Spatial Distribution of the Functions of the Hormone Binding Domain of Receptor that Bind 3-keto-4-ene Steroids, J. Steroid. Biochem. Mol. Biol. 1992, 41, 369-388.
59. Wurtz, J. M., Egner, U., Heinrich. N., Moras, D., Mueller-Fahrnow, A. Three Dimensional Models of Estrogen Receptor Ligand Binding Domain Complexes, Based on Related Crystal Structures and Mutational and Structure-Activity Relationships Data, J. Med. Chem. 1998, 41, 1803-1814.
60. Sadler, B. R., Cho, S. J., Ishaq, K., Chae, K., Korach, K.S. Three-Dimensional Structure-Activity Relationship Study of Nonsteroidal Estrogen Receptor Ligands Using the Comparative Molecular Field Analysis/Cross-Validated r2-Guided Region Selection Approach, J. Med. Chem. 1998, 41, 2261-2267.
61. Brzozowski, A. M. et al. Molecular Basis of Agonism and Antagonism in the Estrogen Receptor, Nature 1997, 389, 753-758.
62. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., Greene, G.L. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of this Interaction by Tamoxifen, Cell 1998, 95, 927-937.
63. Goodsell, D. S., Morris G. M., Olson, A. J. Automated Docking of Flexible Ligands: Applications of AutoDock, J. Mol. Recognit. 1996, 9, 1-5.
64. Rao, M. J., Olson, A. J. Modeling of Factor Xa-Inhibitor Complexes: A Computational Flexible Docking Approach, Proteins: Struct. Funct. Gen. 1999, 34, 173-183.
65. Vedani, A., Huhta, D. W. A New Force Field for Modeling Metalloproteins. J. Am. Chem. Soc. 1990, 112, 269-280.
66. Vedani, A., Dunitz, J. D. Lone-Pair Directionality of H-Bond Potential Functions for Molecular Mechanics Calculations: The Inhibition of Human Carbonic Anhydrase II by Sulfonamides, J. Am. Chem. Soc. 1985, 107, 7653-7658.
67. Meyers, M. J., Sun, J., Carson, K. E., Katzenellenbogen, B. S., Katzenellenbogen, J. A. Estrogen Receptor Subtype Selective Ligands, J. Med. Chem. 1999, 42, 2456-2468.
68. Stauffer, S. R., Huang, Y., Coletta, C. J., Tedesco, R., Katzenellenbogen, J. A. Estrogen Pyrazoles: Defining the Pyrazole Core Structure and the Orientation of Substituents in the Ligand Binding Pocket of the Estrogen Receptor, Bioorg. Med. Chem. 2001, 9, 141-150.
69. Tedesco, R., Youngman, M. K., Wilson, S. R., Katzenellenbogen, J. A. Synthesis and Evaluation of Hexahydrochrysene and Tetrahydrobenzofluorene Ligands for the Estrogen Receptor, Bioorg. Med. Chem. Lett. 2001, 11, 1281-1284.
70. Jorgensen, A. S., Jacobsen, P., Christiansen, L. B., Bury, P. S., Kanstrup, A., Thorpe, S. M., Naerum, L., Wassermann, K. Synthesis and Estrogen Receptor Binding Affinities of Novel Pyrrolo[2,1,5-cd]indolizine Derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 2383-2386.
71. Parnetti, L., Senin, U., Mecocci P. Cognitive Enhancement Therapy for Alzheimer's Disease. The Way Forward, Drugs Future 1997, 53, 752-768.
72. Brufani, M.; Filocamo, L., Lappa, S., Maggi, A. New Acetylcholinesterase Inhibitors, Drugs Future 1997, 22, 397-410.
73. Contreras, J. M., Rival, Y., Chayer, S., Bourguignon, J. J., Wermuth, C. G. Aminopyridazines as Acetylcholinesterase Inhibitors, J. Med. Chem. 1999, 42, 730-741.
74. Wermuth, C. G. et al. 3-Aminopyrid azine Derivatives with Atypical Antidepressant Serotonergic, and Dopaminergic Activities, J. Med. Chem. 1989, 32, 528-537.
75. Sussman, J. L., Silman, I. Atomic Structure of Acetylcholinesterase from Torpedo Californica: A Prototypic Acetylcholine-Binding Protein, Science 1991, 253, 872-879.
76. Harel, M., Sussman, J.L. Quaternary Ligand Binding to Aromatic Residues in the Active Site Gorge of Acetylcholinesterase, Proc. Natl. Acad. Sci. USA 1993, 90, 9031-9035.
77. Raves, M. L., Harel, M., Pang, Y. P., Silman, I., Kozikowski, A. P., Sussman, J. L. Structure of Acetylcholinesterase Complexed with the Nootropic Alkaloid Huperzine A, Nature Struct. Biol. 1997, 4, 57-63.
78. Kryger, G., Silman, I., Sussman, J. L. Structure of Acetylcholinesterase Complexed with E2020 (Aricept): Implications for the Design of New Anti-Alzheimer Drugs, Structure Fold. Des. 1999, 15, 297-307.